Expectations that a safe and effective vaccine or treatment will be available in the critical months of the second wave are fading. Despite the tremendous effort made in terms of its development and the political optimism, the estimates from the companies themselves regarding the latest clinical trials show a more conservative timetable, the approval of which could be extended to the first half of 2021.